Cytokinetics clinical trial
WebFeb 17, 2024 · Cytokinetics ( NASDAQ: CYTK) is a company dedicated to improving patient health and quality of life by developing muscle biology-based medications. Their lead drug candidate, omecamtiv mecarbil,... WebMar 31, 2024 · Cytokinetics Reports ALS Candidate Fails in Phase 3 Trial March 31, 2024 Rare Daily Staff Cytokinetics said that will discontinue the phase 3 trial of reldesemtiv for the treatment of amyotrophic lateral sclerosis after the Data Monitoring Committee found to effect on primary or key secondary endpoints.
Cytokinetics clinical trial
Did you know?
WebJan 7, 2024 · Cytokinetics is conducting start-up activities for SEQUOIA-HCM, the Phase 3 clinical trial of aficamten in patients with obstructive HCM. Cytokinetics is also developing reldesemtiv, a fast skeletal muscle troponin activator, currently the subject of COURAGE-ALS, a Phase 3 clinical trial in patients with amyotrophic lateral sclerosis (ALS). WebJun 17, 2024 · Cytokinetics is readying for the potential commercialization of omecamtiv mecarbil, its cardiac muscle activator, following positive results from GALACTIC-HF, a large, international Phase 3 clinical trial in patients with heart failure.
WebMay 5, 2024 · We have conducted more than 50 clinical trials as we strive to bring important new medicines to patients with diseases like ALS, heart failure, HCM and SMA. Company Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing muscle activators and inhibitors. Our Vision Leadership … WebThis Amendment No. 6 to the Agreement (this “Amendment No. 6”) is entered into as of June 11, 2013 (the “Amendment Effective Date”) by and between Cytokinetics, Incorporated (“Cytokinetics”), a Delaware corporation, having its principal place of business at 280 East Grand Ave., South San Francisco, California 94080 and Amgen Inc., a ...
WebAficamten (formerly CK-3773274, or CK-274) is an investigational, novel, oral, small molecule cardiac myosin inhibitor discovered by company scientists independent of its collaborations, for the potential treatment of hypertrophic cardiomyopathies (HCM). WebJan 11, 2024 · Experimental: CK-3773274 up to 20 mg. Patients will receive doses of 5 mg, 10 mg, 15 mg or 20 mg of CK-3773274 with dose levels guided by echocardiography …
WebApr 10, 2024 · It has been a rough year so far for late-stage biopharmaceutical company, Cytokinetics, Incorporated CYTK. Shares of the company have moved down 20.5% compared with the industry’s decline of 4.7%. bitsy knits fiber artsWebMarguerite Engel - Clinical Trial Assistant - Cytokinetics LinkedIn 25 years experience in the medical field. 17 years in Clinical Research. 13 years working in ALS Clinical … bitsylowhighWebFeb 28, 2024 · SOUTH SAN FRANCISCO, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the U.S. Food and Drug Administration (FDA) issued a Complete... bitsy item variablesWebOct 10, 2024 · A late-stage clinical trial testing an experimental ALS treatment from Cytokinetics, a Californian biotechnology company, will continue as planned following a review of preliminary results by an independent data monitoring committee. ... Cytokinetics aims to enroll 555 patients with ALS in its study, called COURAGE-ALS, and testing the … bitsy jobs gatesheadWebFeb 28, 2024 · Cytokinetics is developing omecamtiv mecarbil, a cardiac muscle activator in patients with heart failure. Cytokinetics is also developing aficamten, a next-in-class … dataset for time series forecastingWebApr 10, 2024 · Cytokinetics is developing aficamten, a next-in-class cardiac myosin inhibitor, currently the subject of SEQUOIA-HCM, the Phase 3 clinical trial of aficamten … bitsy harrison franceWebMar 31, 2024 · Cytokinetics intends to notify all regulatory agencies and clinical trial investigators involved in COURAGE-ALS of these interim findings. The full data set from this trial is being analyzed and more details will be presented at an upcoming medical meeting. Conference Call and Webcast bitsy itch io